Form 4 Tracker
Keros Therapeutics, Inc.
KROS

11 insider filings · Latest: Jun 4, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Jun 4, 2026Jun 8 8:37 PMNima FarzanDirector
Sale
2,625$10.73$28.2K9,767(D)

View →

Jun 4, 2026Jun 8 8:36 PMJulius KnowlesDirector
Sale
2,625$10.73$28.2K10,958(D)

View →

Jun 4, 2026Jun 5 8:15 PMAlpna SethDirector
Sale
2,625$10.72$28.1K9,767(D)

View →

May 15, 2026May 19 8:15 PMJean Jacques BienaimeDirector
Purchase
1,000$10.58$10.6K9,450(D)

View →

Mar 9, 2026Mar 11 8:33 PMJean Jacques BienaimeDirector
Purchase
2,000$11.21$22.4K7,450(D)

View →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Jun 3, 2026Jun 5 9:20 PMAlpna SethDirector
Grant/Award
7,433$10.507,433(D)

View →

Jun 3, 2026Jun 5 8:15 PMMary Ann GrayDirector
Grant/Award
7,433$10.507,433(D)

View →

Jun 3, 2026Jun 5 8:15 PMNima FarzanDirector
Grant/Award
7,433$10.507,433(D)

View →

Jun 3, 2026Jun 5 8:15 PMJean Jacques BienaimeDirector
Grant/Award
7,433$10.507,433(D)

View →

Jun 3, 2026Jun 5 8:15 PMJulius KnowlesDirector
Grant/Award
7,433$10.507,433(D)

View →

Mar 9, 2026Mar 11 8:39 PMCharles W. NewtonDirector
Grant/Award
14,788$11.3514,788(D)

View →